Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Praxis Precision Medicines Inc
(NQ:
PRAX
)
50.35
+0.59 (+1.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Praxis Precision Medicines Inc
< Previous
1
2
3
4
5
6
Next >
Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide
August 08, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
August 07, 2023
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.
Via
Benzinga
Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
August 07, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference
August 03, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Recap: Praxis Precision Medicine Q1 Earnings
May 11, 2023
Via
Benzinga
Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities
June 22, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering
June 15, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
June 15, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA
June 09, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
June 02, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023
June 02, 2023
Via
Benzinga
Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference
June 02, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Says PRAX-628 Can Potentially Be The Best-In-Class Treatment For Focal Epilepsy
May 11, 2023
Praxis Precision Medicines Inc (NASDAQ: PRAX) announced topline results from the PRAX-628 Phase 1 healthy volunteer study evaluating single ascending doses (SAD) and
Via
Benzinga
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 11, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile
May 11, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
April 19, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events
April 17, 2023
Ulixacaltamide essential tremor end-of-phase 2 meeting with FDA scheduled for June 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference
April 06, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
March 11, 2023
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023
March 06, 2023
Via
Benzinga
Praxis Precision Medicines to Present at Upcoming Investor Conferences
March 03, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Dow Jumps Over 300 Points; S&P 500 Rises 1.5%
March 03, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Friday. The Dow traded up 1.03% to 33,343.73 while the NASDAQ rose 1.92% to 11,682.86. The S&P...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
March 03, 2023
Via
Benzinga
Nasdaq Up 150 Points; Crude Oil Rises 1%
March 03, 2023
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 150 points on Friday. The Dow traded up 0.59% to 33,197.08 while the NASDAQ rose 1.32% to 11,614.60. The S&P...
Via
Benzinga
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 03, 2023
Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland.
Via
Benzinga
Dow Surges Over 100 Points; US Services PMI Rises In February
March 03, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday. Following the market opening Friday, the Dow traded up 0.42% to 33,140.85 while the NASDAQ rose 1.02%...
Via
Benzinga
Despite Trial Failure Praxis Still Seeks Advancing Essential Tremor Program Into Phase 3 Study
March 03, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
March 03, 2023
Via
Benzinga
Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3
March 03, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
February 07, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.